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2-Oxoglutarate (2OG) and ferrous iron dependent oxygenases play multiple roles in 
the regulation of gene-expression; they catalyze the demethylation of N-methylated 
chromatin components (histones and nucleic acids)1,2, the hydroxylation of 
transcription factors3, and of splicing factor proteins4. They also catalyze 
hydroxylation of tRNA5-7 and ribosomal proteins8, revealing roles in translation. 
The finding that 2OG-dependent ribosomal oxygenases (ROX) catalyze 
hydroxylation of ribosomal proteins in organisms ranging from prokaryotes to 
humans8 raises questions as to their structural and evolutionary relationships. In 
Escherichia coli, ycfD catalyzes hydroxylation of an arginine-residue in ribosomal 
protein L16, whereas in humans, Mina53 (MYC-induced nuclear antigen) and 
NO66 (Nucleolar protein 66) catalyze hydroxylation of histidine-residues in 
ribosomal proteins rpL27a and rpL8, respectively. The functional assignments of 
the ROX open new therapeutic possibilities for the treatment of human diseases, by 
either ROX inhibition or targeting of differentially modified ribosomes. Despite the 
differences in residue- and protein-selectivities of the prokaryotic and eukaryotic 
ROX, comparison of the crystal structures of human Mina53 and NO66 (hROX) 
with that of ycfD from E. coli, reveal highly conserved folds and novel dimerization 
modes that define a new structural subfamily of 2OG-oxygenases. Structures of 
Mina53 and NO66 in complex with metal and 2OG/2OG analog, with and without 
substrate sequences, reveal how the subfamily has evolved to catalyze hydroxylation 
of different residue sidechains of ribosomal proteins. Comparison of the ROX 
structures with those of the hypoxia-inducible factor asparagine-hydroxylase and 
JmjC histone Nε-methyl lysine demethylases (KDMs) identifies branchpoints in 
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2OG-oxygenase evolution, distinguishing hydroxylases and demethylases involved in 
modifications of the translational and transcriptional machinery. The structures 
reveal new oxygenase activities can evolve by changing the coordination position 
from which the iron-bound oxidizing species reacts. This coordination flexibility has 
likely contributed to the evolution of the remarkably wide range of reactions 
catalyzed by non-heme iron oxygenases. (298 words now; 300 words max) 
 
The 3 ROX on which we conducted structural analyses comprised recombinant human 
Mina53 (aa 26-465), NO66 (aa 183-641) and ycfD from E. coli. All 3 ROX display 
striking similarities in their overall folds: the JmjC catalytic domain is followed by 
helical dimerization and C-terminal ‘winged-helix’ domains9 (Fig. 1b). The same domain 
architecture has recently been observed for an apo-NO66 structure10. The ROX JmjC 
domains consist of 11-12 β-strands, 8 of which (I-VIII) form the double-stranded-β-helix 
(DSBH), which is stereotypical of 2OG-oxygenases (Fig. 1b)11,12.  
 
The dimerization domains possess a 2-fold symmetry and comprise a bundle of 3 α-
helices (Supplementary Fig. 2). The dimers are stabilized by both electrostatic/hydrogen-
bonds and hydrophobic interactions. Consistent with a catalytic role for this domain, a 
dimerization blocking substitution, I221RycfD ablates activity. The C-terminal domains, 
which are also required for activity, are reminiscent of other ‘winged-helix’ domains 
involved in protein-protein/-nucleic acid interactions9; but the overall negative charge 
suggests that they do not bind nucleic acids. In contrast to ROX, other JmjC-
hydroxylases (FIH13,14, TYW56, JMJD515 and JMJD64) and the KDMs do not contain 
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‘winged-helix’ domains (Fig. 2). Analyses of the combined structures lead to the proposal 
that ROX fold evolved into those of other JmjC-hydroxylases and KDMs partly via loss 
of the ‘winged-helix’ domain which enabled other roles for the C-terminal helical bundle, 
e.g. dimerization as in FIH. 
 
The ROX structures were determined in complex with Mn(II) and 2OG/N-oxalylglycine 
(NOG), replacing Fe(II) and 2OG. As for most 2OG-oxygenases, the metal is 
octahedrally coordinated by a 2-His-1-carboxylate triad on DSBH βII and βVII11,12. Two 
coordination sites are occupied by the 2OG/NOG oxalyl group leaving one vacant for 
H2O/O2 binding (Fig. 4, Supplementary Fig. 5). With ycfD the 2OG C5-carboxylate is 
positioned to form salt bridge with Arg140ycfD on DSBH βIV. This arrangement is 
interesting because with other 2OG-oxygenases where the 2OG C5-carboxylate interacts 
with an Arg–residue, the Arg is on βVIII11,12. In hROX, the 2OG C5-carboxylate 
interacting residue is a lysine (Lys194Mina53, Lys355NO66) from βIV, as observed in most 
JmjC enzymes including the JmjC-hydroxylases and KDMs. These observations support 
the proposal that the eukaryotic JmjC-hydroxylases and KDMs evolved from the 
prokaryotic ycfD/ROX. 
 
Initial attempts to obtain ROX-substrate complexes with ribosomal protein derived 
substrates were unsuccessful. Kinetic studies reveal relatively high Km values for 
substrate fragments; we therefore pursued a number of alternative strategies. We 
successfully employed disulfide cross-linking to obtain hROX-substrate complexes, as 
used for other 2OG oxygenases16,17 (Supplementary Fig. 4). Structures were obtained for 
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wildtype NO66·rpL8-G220C (complex 1), L299C/C300S-NO66·rpL8-G220C (complex 
2), and S373C-NO66·rpL8-G214C (complex 3) pairs in combination with NOG/ Mn(II). 
Electron densities corresponding to rpL8 residues 215-223 (complex 1), 213-223 
(complex 2) and 212-223 (complex 3) were observed at the NO66 active site (Fig. 3, 
Supplementary Fig. 4). In these structures, rpL8 residues (215-219) including the 
hydroxylated His216 adopt near identical conformations (rmsd, 0.29-0.36 Å for Cα 
atoms). In the light of NO66·rpL8 structures, we then identified a Mina53 residue suitable 
for cross-linking: Y209C-Mina53 crystallized in complex with rpL27a-G37C, Mn and 
2OG with electron density observed for rpL27a residues 36-44 (Fig. 3). 
 
The rpL27a/rpL8 substrates bind to Mina53/NO66 in a conserved manner (rmsd, 
rpL27a38-43, and rpL8215-220 Cα, 0.8 Å) with the same N-/C- directionality, as for FIH13,14 
and for one KDM, PHF818 (and likely other KDM2/7 subfamily members) but differing 
from that for most KDMs (JMJD2A/KDM4A19,20, JMJD3/KDM6B21, UTX/KDM6A22) 
(Fig. 2). The substrates bind in shallow channels on the hROX surface and form multiple 
interactions/hydrogen-bonds with DSBH βI, βII, βVIII and the extended loop between 
βIV and βV. Notably, both the rpL27a and rpL8 substrates make hydrophobic contacts 
with the WH-domains in Mina53 and NO66 (Supplementary Fig. 3). In addition, Mina53 
forms an important salt-bridge interaction with Arg42rpL27a with its Asp333Mina53 located 
on the α-helix connecting the dimerization and WH domains. 
 
The general binding mode of the hydroxylated residues is conserved between Mina53 and 
NO66, i.e. they bind in deep pockets and the positions of the hydroxylated β-methylenes 
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near superimpose. Modeling studies imply that the prokaryotic ycfD will bind its L16 
substrate Arg81 in an extended pocket such that the oxidized C-H bonds (3-pro-R in 
Arg81L16 analogous to 3-pro-S in His39rpL27a and His216rpL8) project towards the metal 
(Fig. 4). With hROX, the binding of His39rpL27a/His216rpL8 involve a series of hydrogen-
bonds to backbone amides/ sidechains of hROX residues: Gln136Mina53/Arg297NO66, 
Asn165Mina53/Asn326NO66, Tyr167Mina53/Tyr328NO66 and Ser257Mina53/Ser421NO66 (Fig. 3). 
With ycfD, an ensemble of models predicts that Arg81 will bind in a hydrophobic cleft 
lined by Tyr129ycfD and Met112ycfD sidechains (Supplementary Fig. 8).  
 
Comparison of the ROX and KDM/FIH active sites (Fig. 2, 4a) clearly identifies 
structural features characteristic of JmjC-hydroxylases and -demethylases. Although in 
ROX and KDM4A·H3K9me2 (PDB: 2OX0)20  complex structures the substrates bind 
with ‘opposite’ N- to C- directionality, the histone K9men side chain is positioned 
similarly to the histidine-sidechain including methylenes that undergo ROX-catalyzed 
hydroxylations. However, because KDM-catalyzed hydroxylations occur at the termini of 
Nε-methyl lysine-residues, their target residues do not penetrate as far into the enzyme 
(Fig. 4a). The ROX lack 2 flexible loops linking α4-βI (aa 164-175) and α9-α10 (aa 302-
317) in KDM4A, which are conserved in KDM subfamilies and which form important 
interactions with the H3 histone Kmen sidechain, exemplifying how the ‘core’ ROX-fold 
has been modified by evolution to accommodate the Kmen sidechain. 
 
FIH, like ROX, catalyzes β-hydroxylation, of an Asn-residue of its HIF-α transcription 
factor substrate23 and of other residues including histidines in ankyrin repeats24. 
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Superimposition of hROX/FIH-substrate structures is interesting from catalytic and 
evolutionary perspectives. Although both FIH/hROX catalyze histidine 3S-hydroxylation, 
the positions of their substrate imidazoles is strikingly different (Fig. 4a). The positioning 
of hydroxylated methylenes relative to the metal differs substantially: in the overlaid 
structures, the angle between the metal and the Cβ atoms of the His39rpL27a/His216rpL8 
(hROX substrate) and Asn803HIF1α (FIH substrate) is ~50° (Fig. 4a), demonstrating that 
the reactive oxidizing intermediates (Fe(IV)=O)12,25,26 reacts from different coordination 
positions in different oxygenases.  
 
The rpL8 (NO66 substrate) has an Asn at the -1 position relative to the hydroxylated 
His216. The Asn215rpL8 methylene is only slightly (0.5 Å) further away from the metal 
than that of His216rpL8, revealing exquisite sensitivity of oxygenase catalysis to geometric 
positioning. There is a striking correlation in the binding modes of 
Asn215rpL8/Asn803HIF1α to NO66/FIH, even though one residue is hydroxylated and one 
not. Both the primary amides of Asn215rpL8/Asn803HIF-1α hydrogen-bond with primary 
amides, i.e. Asn376NO66 and Gln239FIH. Collectively these observations reveal 2OG-
oxygenases can evolve new activities not only by ‘directly’ altering the nature of 
enzyme-substrate interactions, including by altering the directionality of substrate 
binding, but also by ‘flipping’ the coordination position from which the ferryl-
intermediate reacts. In contrast to NO66/FIH, the ycfD and Mina53 substrates do not 
contain an Asn adjacent to the hydroxylated residue. Instead, at the analogous position to 
Asn215rpL8, L16/ycfD and rpL27a/Mina53 have hydrophobic residues, i.e. Val80L16 and 
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Leu38rpL27a (Fig. 3, 4). Leu38rpL27a binds in a hydrophobic cleft lined by residues from 
DSBH βII and the insert between βIV and βV (Fig. 2). 
 
The combined structures reveal the observed mode of ROX hydroxylations could have 
evolved into the FIH/related JmjC Lys-hydroxylation and KDM type 
hydroxylation/demethylation modes by altering the coordination position from which the 
ferryl-oxygen reacts and by engineering the depth of substrate penetration into enzyme. 
Structurally informed phylogenetic analyses, coupled to the observation that NO66 is 
more widely distributed than FIH/Mina53 lead to the proposal that prokaryotic ycfD 
evolved into NO66, which is a branchpoint leading to the JmjC-hydroxylases/ 
demethylases in eukaryotes. 2OG-oxygenases are one of the most catalytically flexible of 
all enzyme-families. Recent work reveal FIH manifests remarkable catalytic promiscuity, 
including the ability to oxidize not only Asn- but also Asp-, His-, Ser- and even 
hydrophobic Leu-residues27. Our structural studies reveal that ROX react with substrates 
via a different but evolutionarily related binding mode to FIH. The catalytic capabilities 
of 2OG-oxygenases for protein oxidations thus likely extend beyond those presently 
identified.  
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METHODS SUMMARY  
Recombinant human Mina53, NO66 and bacterial ycfD were produced in E. coli 
BL21(DE3) and purified by metal affinity (or cation exchange) and size exclusion 
chromatography. Assays comprised incubation with Fe(II), 2OG and substrate under 
appropriate conditions followed by MALDI-TOF and/or 2OG turnover assays. Crystals 
were grown by vapor diffusion (Supplementary Table 1) and cryo-cooled in liquid 
nitrogen. Data were collected on SLS X10SA, ESRF BM16 and Diamond MX 
beamlines. Mina53 and ycfD structures were solved by SAD (Single-wavelength 
Anomalous Diffraction) or by SIRAS (Single Isomorphous Replacement with 
Anomalous Scattering) using SeMet derivatives. The NO66 structure (PDB ID: 4DIQ) 
was solved by molecular replacement using the Mina53-JmjC domain (PDB ID: 2XDV). 
Phases of the substrate complex structures were solved by MR using apo-structures 
(4BU2/Mina53, 4DIQ/NO66). Supplementary Tables 2-4 give data processing and 
refinement statistics. 
Full Methods and associated references are in the online version. 
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HIF; TYW5: tRNA wybutosine-synthesizing enzyme 5; JMJD5 and 6: JmjC-domain 
containing protein 5 and 6; PHF8: PHD (plant homeo domain) finger protein 8; UTX: 
ubiquitously-transcribed X chromosome tetratricopeptide repeat protein. 
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FIGURE LEGENDS 
 
Figure 1: The overall folds of the ribosomal oxygenases. 
a, Reactions catalyzed by ROX and related oxygenases. b, Ribbons representations of 
ycfD, NO66 and Mina53 homodimers. The monomers contain a JmjC domain containing 
the double-stranded-β-helix (DSBH) core present in all 2OG-oxygenases (blue) followed 
by dimerization (yellow) and C-terminal ‘winged-helix’ domains (red). Domain 
architecture and a schematic representation of the DSBH core β-strands (βI–VIII) that 
form major (grey, βI, VIII, III and VI) and minor sheets (blue, βII, VII, IV and V) is 
shown boxed. The insert between βIV and βV (purple) is involved in substrate binding. 
The 3 iron-coordinating residues (HXD..H) are on the βII and βVII strands (black 
circles). 2OG is in green sticks; the 2OG C5-carboxylate binding residue, Lys 
(Mina53/NO66) or Arg (ycfD) from βIV is a black circle. 
 
Figure 2: Comparison of the substrate binding by ROX/ JmjC enzymes. 
Ribbons representations from ROX and related 2OG-oxygenase-substrate complexes: a, 
Mina53·Mn·2OG·rpL27a(32-50) (P212121, 2.05 Å), b, NO66·Mn·NOG·rpL8(205-224) (C2, 
2.35 Å), c, FIH·Fe·NOG·HIF-1α(786-826) (PDB: 1H2K), d, KDM4A·Ni·NOG·histone 
H3K9me2 (PDB: 2OX0), e, UTX/KDM6A·Ni·NOG·histone H3K27me3 (PDB: 3AVR), f, 
PHF8·Fe·NOG·histone H3K4me3K9me2 (PDB: 3KV4). For comparison, the DSBH core 
of each structure is in a similar orientation. Note the directionality of substrate binding in 
the JmjC domains. The active site metals (Fe/ surrogate) are color-coded spheres. CAD, 
C-terminal transactivation domain of HIF-1α. Analyses of the structures reveal that the 
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ROX overall folds (a-c), oligomerization states and active site architectures are 
evolutionarily conserved. 
 
Figure 3: Features of ROX-substrate binding. 
Ribbons representations of Mina53 (a) and NO66 (b) monomers showing difference 
electron density (Fo-Fc OMIT) for substrates contoured to 3σ (right panels). Left panels 
show active site surface representations, showing key hydrogen-bonds / polar interactions 
(dotted lines) with substrates. a, With Mina53, the His39rpL27a imidazole nitrogens form 
hydrogen-bonds with Tyr167/ Ser257 (NδHis39-OHTyr167 2.9 Å; NεHis39-OγSer257 3.1 Å). b, 
In NO66, His216rpL8 is similarly bound in a deep pocket; the His216rpL8 imidazole 
nitrogens form hydrogen-bonds with Tyr328/ Ser421 (NδHis216-OHTyr328 3.2 Å; NεHis216-
OγSer421 2.7 Å) and hydrophobic interactions with Ile244, that project its pro-S hydrogen 
toward the metal (metal-β-CH2, 4.4 Å). While Mina53 (a) uses 4 primary amides, 
Asn101, Gln136, Gln139 and Asn165 to interact with rpL27a backbone amides, NO66 
(b) uses 2 arginines at 272 and 297 to hydrogen-bond with the Asn215rpL8 sidechain and 
His216rpL8 backbone. The role of the serine (Ser257Mina53, Ser421NO66 and possibly 
Ser199ycfD) and tyrosine (Tyr167Mina53, Tyr328NO66 and possibly Tyr129ycfD) in binding 
the hydroxylated His/Arg is likely conserved in all ROX. 
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Figure 4: Proposed sequence of evolution of active metal chemistry of ROX and 
related JmjC 2OG-oxygenases.  
The figure compares views from the active sites of representative JmjC enzymes and 
suggests how the ROX fold evolved into JmjC protein hydroxylases and the KDMs. 
Structurally informed cross-genomic bioinformatic analyses imply that the ROX are the 
earliest identified JmjC 2OG-oxygenases. ycfD and NO66 both exist in prokaryotes but 
only NO66 is identified in eukaryotes. Phylogenetic analyses coupled to the analyses of 
the active sites and structural similarities imply NO66/close-relatives are precursors of 
Mina53 and other JmjC-hydroxylases and KDMs. a, Upper panel: structure based 
alignment of ROX, FIH, PHF8 and KDM4A with DSBH core β-strands labeled βI-VIII, 
iron-coordinating and the 2OG C5-carboxylate binding residues in red and green. Lower 
panels: analyses of active sites suggest conservation of metal-/2OG-binding in ROX, FIH 
and KDMs; note the 2OG C5-carboxylate binding residue (usually from βIV in JmjC-
enzymes), changes from an Arg (in ycfD) to a Lys (in hROX, JmjC-hydroxyalses/KDMs) 
(Supplementary Fig. 5). b, The figures show overlays of the NO66/Mina53, NO66/FIH, 
NO66/KDM4A active site views. The hydroxylated β-methylenes near superimpose in 
ROX, such that the oxidized 3-pro-S C-H bonds (red arrows, His39rpL27a and His216rpL8) 
project toward the metal. The spatial relationship of the hydroxylated C3/Nε-methyl 
carbon with respect to the metal (and associated reactive oxidizing species) is conserved 
in ROX and the demethylases, e.g. KDM4A, but not in FIH. Note the different 
hydroxylation positions, but the similar orientation of Asn803CAD/FIH (hydroxylated) and 
Asn215rpL8/NO66 (not hydroxylated).  
Online Methods 
Ribosomal Oxygenases are Structurally Conserved from Prokaryotes to 
Humans 
 
Recombinant protein production and enzyme assays 
cDNA sequences encoding N-terminally truncated Mina53 (residues 26-465) and NO66 
(residues 183-641) were PCR amplified from Mammalian Gene Collection (MGC) (accession 
no.: BC014928 and BC011350, respectively) and cloned into pNIC28-Bsa4 vector. Full length 
ycfD was cloned into pET-28a(+) vector (Novagen, Madison, WI, U.S.A.) as described1. 
Stratagene’s QuickChange site-directed mutagenesis kit was used to make all ROX mutations 
using the above constructs as templates. 
 
ROX wildtype enzymes/ variants were produced as native His6-tagged proteins in Escherichia 
coli BL21(DE3) as described1. For crystallization experiments, selenomethionine (SeMet) 
derivatized enzymes, SeMet-Mina53 and SeMet-ycfD were produced in E. coli BL21(DE3)-
R3-pRARE2 and BL21(DE3) strains, respectively. In general, cells were grown in Le Master 
media2 (alternatively in SelenoMethionine Medium Base plus Nutrient Mix) supplemented 
with selenomethionine  (40-50 mg·mL-1) and kanamycin (30 µg·mL-1) at 37 °C (while shaking 
at 200 rpm) until an OD600 (optical density at 600 nm) of 1.2 (SeMet-Mina53) or 0.6 (SeMet-
ycfD) was reached. Protein expression was then induced with 0.2 mM (SeMet-Mina53) or 1.0 
mM (SeMet-ycfD) isopropyl β-D-1-thiogalactopyranoside (IPTG) and allowed to continue for 
18 h at 18 °C. 
 
All native/ SeMet-derivatized proteins were purified from cell lysates using immobilized Ni2+ 
affinity chromatography with gradient elution using imidazole and/or ion-exchange 
chromatography. For ycfD, imidazole was removed by buffer exchange to 50 mM Hepes-Na 
pH 7.5 using a PD10 desalting column followed by a further purification using Q-Sepharose 
HP anion exchange chromatography. For Mina53 and NO66, the His6-tag was removed by 
incubation with TEV protease followed by a final-step purification using size-exclusion 
chromatography in 50 mM Hepes-Na pH 7.5, 500 mM NaCl, 5% (v/v) glycerol, 0.5 mM 
TCEP (tris(2-carboxyethyl)phosphine). Proteins were concentrated to 10-30 mg·ml-1 and 
were of >95 % purity, as determined by SDS-PAGE. All columns were supplied by GE 
Healthcare. Assays were performed as described1. 
 
Crystallization 
Crystals of Mina53, NO66 and ycfD complexes were grown under the conditions described 
in Supplementary Table 1. In general, crystals were cryoprotected by transferring to a 
solution of mother liquor supplemented with 20% (v/v) ethylene glycol (Mina53/ NO66), 
25% (v/v) glycerol (ycfD) before being cyro-cooled in liquid N2.  
 
Data collection and processing  
As described in Supplementary tables 2-4, data on native and SeMet-derivatized crystals were 
collected at 100K using synchrotron radiation at the Swiss Light Source (SLS) beamline 
X10SA and Diamond Light Source (DLS) beamlines. The data were processed as outlined in 
Supplementary Tables 2-4.  
 
Structure solution and refinement  
Mina53 structures 
Structure solution by SIRAS: SHAKE-AND-BAKE3 was used to identify 5 Se-positions in the 
SeMet-Mina53 dataset (P4332 space group); refinement of heavy atom parameters and phasing 
was carried out with SHARP4 using the single ismorphous replacement with anomalous 
scattering (SIRAS) method with Mina53 (native) as the native and SeMet-Mina53 as the 
derivative dataset. The electron density map after density modification with SOLOMON5 was 
of good quality; automated model building with ARP/wARP resulted in a >80% complete 
model with one Mina53 molecule per asymmetric unit, which corresponds to an unusually high 
solvent content of ~75%. Refinement was carried out with BUSTER6 and after several cycles 
of manual rebuilding with COOT7, the model converged to 19.7% Rcryst and 22.9% Rfree. 
Atomic coordinates and structure factors for this structure are deposited in the PDB database 
with the accession code 2XDV. 
 
Structure solution by SAD: Using Patterson seeding and dual-space direct methods, SHELXD 
(SHELXCDE pipeline8/ CCP4 suite9) located 6 out of 8 possible Se-sites using a SeMet-
Mina53 SAD data set. Refinement of substructure solution followed by density modification 
with SHELXE8 resulted in good-quality initial phases to 2.8 Å resolution. Automated model 
building with BUCCANEER10 resulted in a model where core regions including the JmjC and 
dimerization domains were built. Iterative refinement using CNS 1.311 and model building 
using COOT7 continued until Rfree was around 30%. Final rounds of manual fitting using 
COOT7 and refinement using a combination of CNS 1.311 and PHENIX12 continued until 
Rcryst/Rfree no longer improved (Supplementary Table 2). This structure (deposited with PDB 
ID: 4BU2) was then used as a search model to solve the structure of Y209C Mina53 in 
complex with rpL27aG37C by molecular replacement with PHASER13 (P212121 space group, 
resolution, 2.05 Å). The quality of all Mina53 structures was validated using MOLPROBITY14 
with >95% of the residues in the favored region of the Ramachandran plot. 
 
NO66 structures 
An N-terminally truncated form of Mina53 (residues 30-260), comprising the JmjC domain, 
was used as a search model for molecular replacement using PHASER13. The two molecules in 
the asymmetric unit of NO66 were readily located, but the electron density away from the 
JmjC core of NO66 was ambiguous. Density modification with RESOLVE15 as implemented in 
PHENIX12, which took advantage of the 2-fold non-crystallographic symmetry (in a P21212 
space group), led to a significant map improvement and allowed automated model building 
with BUCCANEER10. Refinement was carried out with REFMAC16; after several cycles of 
manual rebuilding with COOT7, the model converged to 18.5% Rcryst and 23.1% Rfree. Atomic 
coordinates and structure factors for this structure are deposited in the PDB (accession code 
4DIQ). The remaining NO66 structures including those in complex with substrate rpL8, were 
solved in P21 or C2 space groups (resolution, 2.15-2.50 Å) with 2-4 molecules per asymmetric 
unit (Supplementary Table 3) using the NO66/P21212 structure (PDB ID: 4DIQ) as a search 
model. Iterative rounds of model building using COOT7 and refinement using PHENIX12 
and/or CNS 1.311 were performed until the decreasing Rcryst and Rfree no longer converged 
(Supplementary Table 3). All residues were in acceptable regions of Ramachandran plots as 
calculated by MOLPROBITY14. 
 
YcfD structures  
SOLVE was used to locate 17 out of 22 possible Se-sites using the SeMet-ycfD dataset. 8 pairs 
of sites were related by non-crystallographic symmetry. The initial electron density map after 
solvent flattening density modification with RESOLVE15 was of good quality and automated 
model building resulted in a model where core regions (60% of residues in the crystallized 
protein’s sequence) of both molecules in the asymmetric unit were built. Refinement and fitting 
cycles were performed using PHENIX12 and COOT7 that converged to a final 19.47% Rcryst and 
Rfree 24.98%. Phasing and refinement statistics are summarized in Supplementary Table 4.   
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 S2 
Supplementary Figure 1: Schematic protein topologies of ROX and related 2OG oxygenases.  
 
a  
 
b 
 
  
c 
 
d 
 
  
e 
 
f 
 
 
 
Protein topologies of (a) Mina53·Mn·2OG·rpL27a(32-50), (b) NO66·Mn·NOG·rpL8(205-224), (c) ycfD·Co·2OG, (d) 
FIH·Fe·NOG·HIF-1α(786-826) (PDB: 1H2K), (e) PHF8·Fe·NOG·histone H3K4me3K9me2 (PDB: 3KV4), and (f) 
KDM4A·Ni·NOG·histone H3K9me2 (PDB: 2OX0) (substrates are not shown). DSBH core elements, labeled βI–βVIII, 
are in smudged green, helices are cyan, additional β-strands are red, random coils are black and the insert between the 
fourth and fifth β-strands is blue. Note not all the 2OG oxygenases maintain antiparallel hydrogen-bond pairing 
between βII and βVII even though the φ/ψ angles (βII) are within the β-region of the Ramachandran plot. Figures were 
generated using TopDraw1. 
 
 S3 
Supplementary Figure 2: ROX dimerization domains. 
 
a, Comparison of dimerization domains in ROX and FIH. b, Intermolecular interactions observed at dimerization 
interfaces. c, Disruption of ROX dimerization leads to loss of activity: (i) ycfD dimerization domain showing the I211R 
substitution site; (ii) Non-denaturing gel electrophoresis demonstrates disruption of dimerization in I211R ycfD; (iii) 
The I211R variant is inactive as shown by MALDI-MS assay in the presence of appropriate cosubstrates/ cofactors; (iv) 
FIH dimerization domain showing the L340 substitution site, the point variant was shown to be predominantly 
monomeric and to have lost catalytic activity2.  
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The dimer interfaces in the ROX are related to that observed in FIH; we propose the FIH dimerization fold evolved from 
that of the ROX 3,4. The large buried surface area (>3000 Å2 ) within all ROX dimerization domains is sufficient for 
oligomerization in solution, as reported for NO665. The interactions observed in dimerization include both hydrogen 
bonds/ electrostatic interactions and hydrophobic interactions.  
 
In the ycfD dimerization domain, residues involved in hydrophobic interactions are mainly from α2: Val242, Met247, 
Leu250, Met253, Met254, Leu257 and Ile258. Leu255ycfD is positioned at the center of a hydrogen-bond network 
(Asp248A-Arg251A-Asn259B) between two ycfD monomers which due to a 2-fold symmetry, creates a total of 4 
hydrogen bonds. Further, Asn226ycfD amide-N is positioned to form a hydrogen bond to the hydroxyl group O of Thr207 
and Arg208 hydrogen bonding with carbonyl O of Gly224. Other hydrophobic/aromatic clusters found in ycfD are 
formed by the sidechains of Leu210, Leu223, Tyr217 (α1), Phe264, Trp267, Phe268 and Phe271 (α3) from monomer A 
and Val242, Met247, Leu250 (α2) from monomer B. 
 
As in ycfD, in NO66 there is an apparent salt-bridge interaction in the dimer interface, i.e. between Arg474 and Asp495 
(Arg474 NH1-Asp495 Oδ1, 2.9Å; Arg474 NH2-Asp495 Oδ2, 2.7Å), which links the α2 and α3 helices of opposite 
monomers. A similar ‘complex salt-bridge’ is observed in Mina53 between Arg313 and Glu320/Asp317 (Arg313 NH1-
Glu320 Oε2, 3.2Å; Arg313 NH2-Glu320 Oε1, 2.7Å; Arg313 NH2-Asp317 Oδ1, 2.9Å) that connects α2 helices of 
different monomers. Backbone amide hydrogen bonding additionally occurs between NO66 residues, Asn426 and 
Leu454, Arg452 and Trp428, Phe450 and Gly429. Mina53 also has backbone-to-sidechain interactions between 
residues from flexible loops connecting α1-α2 and α2-α3 helices (Gln297 O-Lys331 Nζ, 3.7 Å; Ser300 Oγ-Glu324 O, 
3.1 Å). The role of hydrophobic/aromatic clusters in dimerization is apparent in NO66 where the α2 helices from 
different monomers are further apart when compared with those of ycfD and Mina53 and hence have less buried surface 
area. However, in NO66, an apparent hydrophobic cluster is formed between the N-terminal part of α1 and the C-
terminal part of α2. Trp428NO66 (Trp264 in Mina53) is positioned at the start of the α1 helix of monomer A and forms 
the center of a hydrophobic cluster, interacting with residues Phe431, Ile435 and Leu432 on monomer A, and Val481, 
Leu484, Met462, Phe477 and Pro455 on monomer B. Trp428 also forms an apparent cation-pi interaction with residue 
Lys480. A similarly positioned Trp264 in Mina53 maintains hydrophobic contacts with Phe267 and Leu268 of the same 
monomer and with Ile290, Pro291 and Leu294 of the other in addition to a cation-pi interaction with Arg307. Other 
hydrophobic contacts in Mina53 dimerization involve the α1 and α2 helices of different monomers including between 
the sidechains of Leu308/α2 (with Leu319/α2 and Phe267, Leu268, Thr271 of α1) Leu312/α2 (with Ile272/α1 and 
Leu315/α2) and Phe277/α1 (interacting with Val276, Leu269 and Ile272 of α1). 
 
 S5 
Supplementary Figure 3: Interaction of the ROX C-terminal ‘winged helix’ (WH) domain with their respective 
ribosomal protein substrates. 
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The figure shows how the ROX C-terminal domains interact with their substrates. A DALI search6 indicates that a 
close structural homolog of the ROX C-terminal domain is the ‘peptide clamp’ (‘winged helix’ WH) domain of MccB, 
an enzyme involved in the biosynthesis of the microcin C7 antibiotic7. The WH  domains, a subtype  of  the  helix-
turn-helix (HTH) family, are nucleic acid/ protein interacting domains and occur in  different  cellular  pathways from 
transcriptional regulation to RNA processing8. Although the overall negative charge of ROX WH domains suggests 
that they do not interact with nucleic acids, it is notable that the prokaryotic ribosomal proteins L6, which is located 
proximate to L16 in the ribosome9, and the transcriptional regulator PhoP contain WH folds10; the latter is interesting 
because in the E. coli K12 genome the ycfD gene is located adjacent to those for the PhoP/PhoQ two component 
signaling system, which is involved in stress responses11. a, General topology of the C-terminal ‘winged helix’ like 
(WH) domain showing binding sites for rpL27a (magenta) and rpL8 (orange) involving hROX residues from an 
extended loop between β3-β4. Figures b-e compare the WH domains in MccB (b), Mina53 (c) and NO66 (d) showing 
the interactions observed between this domain and the substrate(s). Note that both the rpL27a and rpL8 substrates 
make hydrophobic contacts with the WH domains in Mina53 (Met405 and Met406) (c) and NO66 (Val576 and 
Tyr577) (d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 S6 
Supplementary Figure 4: NO66-substrate complexes 1, 2 and 3 showing cross-linking sites (red arrows) and 
difference electron density (Fo-Fc OMIT) for the substrate residues contoured to 3σ. 
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The figure shows different disulfide cross-linking sites (red arrows) that form NO66·rpL8 cysteine-disulfide pairs under 
equilbriating conditions. Analyses of the 2OG-oxygenase-protein substrate complexes reveal that substrate residues at 
the ±2 positions relative to their hydroxylation targets have interactions with enzyme residues within an ~12 Å radius of 
the metal. To obtain stable NO66-rpL8 complexes, we therefore engineered NO66 variants substituting Cys-residues 
within ~12 Å radius of the metal at positions considered likely involved in substrate binding based on the other 2OG-
oxygenase-protein substrate complexes12-14. On the peptide substrate sequence, we also substituted Cys residue at 
±2 positions relative to the hydroxylation target residue. MS assays were then used to identify best cross-linking yields 
for the NO66-rpL8 pairs under equilibrating conditions. The following cross-linked pairs were used for 
crystallization: wildtype NO66·rpL8G220C, a double NO66 variant L299C/C300S·rpL8G220C, and two singly 
substituted variants, S373C·rpL8G214C and S421C·rpL8H218C. Structures were obtained for wildtype 
NO66·rpL8G220C (complex 1, b), L299C/C300SNO66·rpL8G220C (complex 2, c), and S373CNO66·rpL8G214C 
(complex 3, d) in combination with NOG/ Mn(II) in C2 space group, 2.25 -2.50 Å resolution with 2 molecules/ 
asymmetric unit; rpL8 residues 215-223 (complex 1), 213-223 (complex 2) and 212-223 (complex 3) were observed 
bound to the NO66 active site. Figure a shows superimposition of the three complex structures; note that the key rpL8 
residues (215-219) including the hydroxylated His216 are observed in near identical conformations (rmsd, 0.29-0.36 Å 
for Cα atoms) suggesting no/minimal effect of cross-linking. 
 
 
 
 
 
 S7 
Supplementary Figure 5: Comparison of 2OG/ co-substrate binding in ROX and representative 2OG oxygenases.  
 
 
 
The identity of the basic residue (Arg or Lys) that binds the 2OG C5-carboyxlate via electrostatic interactions is 
indicated along with which of the eight DSBH (I to VIII) strands it is located on. The occurrence and positioning of 
the basic Arg/Lys is subfamily characteristic. 2OG binding also involves other polar residues including alcohols, i.e. a 
Ser (βVIII, part of ‘RXS’ motif as reported in e.g. DAOCS, ANS, FTO, Algal P4H) or Thr (βII, e.g. as in JMJD3, 
JMJD6, PHF8, UTX) or Tyr (non-DSBH β-strand, e.g. as in FIH, KDM4A, ABH2, PHD2) and sometimes, water 
molecule(s) (reviewed in 15-17). In an analogous position to the serine of ‘RXS’ motif (βVIII), the hROX have 
histidine-residues, His253Mina53/His417NO66 (βVIII), that form part of a hydrogen-bond network involving 
Thr255Mina53/Thr419NO66 (βVIII), a water molecule and the 2OG carboxylate. Although ycfD has Asn197 at this 
position (βVIII), it is a Ser114 from βI that is positioned to hydrogen bond with the 2OG C5-carboxylate. 
Abbreviations used: DAOCS, deacetoxycephalosporin C synthase; ANS, anthocyanidin synthase; FTO, fat mass and 
obesity associated protein; P4H, prolyl-4-hydroxylase; FIH, asparaginyl hydroxylase factor inhibiting HIF (hypoxia-
inducible factor); JMJD3 and 6: JmjC-domain containing protein 3 and 6; PHF8: PHD (plant homeo domain) finger 
protein 8; UTX: ubiquitously-transcribed X chromosome tetratricopeptide repeat protein; ABH2, alkylated DNA 
repair protein (AlkB) homolog 2; PHD2, prolyl hydroxylase domain 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 S8 
Supplementary Figure 6: Ligplot presentations of hROX-substrate complexes. 
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Ligplot representations of (a) Mina53.rpL27a and (b) NO66.rpL8 complexes showing electrostatic interactions (dotted 
lines) between hROX and their ribosomal protein substrates. For clarity, not all the observed hydrophobic interactions 
are not shown. 
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Supplementary Figure 7: Conformational changes on substrate binding in hROX. 
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The figure shows conformational changes at the domain and residue levels in (a) Mina53 (in dark salmon and red 
with/without rpL27a, light blue) and (b) NO66 (in slate and cyan with/without rpL8, orange). The overall movement 
observed for the C-terminal WH domain on substrate binding is more significant in Mina53 as compared to NO66 a, 
The inset highlights local changes to the active site region in Mina53 in the presence (green sticks)/ absence (yellow 
sticks) of substrate; Mina53 uses an acidic residue, Asp333 located on an α-helix connecting the dimerization and WH 
domains, to form an apparently important salt-bridge interaction with Arg42rpL27a. In the substrate-unbound form, 
Asp333Mina53 has two alternative conformations indicating flexibility. The NO66 substrate, rpL8 has an Ile219 at the 
analogous position to Arg42rpL27a that makes hydrophobic contacts with the Tyr577 sidechains from WH domain of 
NO66 (b). 
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Supplementary Figure 8: Predicted binding mode of L16 to prokaryotic ycfD. 
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The figure illustrates predicted binding mode of prokaryotic ribosomal L16 (yellow) to ycfD from E. coli (green). A 
model complex of ycfD with Mn(II), NOG and L16 (residues Pro77-Lys84) was generated using ycfD-SeMet and 
Mina53·Mn·2OG·rpL27a(32-50) structures as the templates. The ycfD·Mn·NOG·L16(77-84) model was energy minimized 
using CNS (version 1.3)18 without applying external energy terms. a, Ribbons representations from 
ycfD·Mn·NOG·L16(77-84) model complex. b, Surface representations of the ycfD complex, predicting key hydrogen-
bonds / polar interactions (dotted lines) with L16. The hydroxylated Arg81L16 is predicted to bind in a pocket defined 
by the Tyr129 and Met112 sidechains, which likely form pi-cation and hydrophobic interactions with Arg81L16 
sidechain. The Arg81 guanidino group is predicted to make electrostatic interactions with the Asp110ycfD carboxylate 
and hydrogen-bonds to Ser199ycfD. 
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Supplementary Figure 9: Comparison of active site chemistry of ROX and related enzymes. 
 
 
  
 
 
 
 
 
 
 
 
The figure compares active site chemistry in representative 2OG oxygenases and directionality of the peptide substrate 
binding through the active site. Red arrows indicate hydroxylation sites. The active site metals (Fe/ Fe-surrogates, Mn 
or Ni) are in color-coded spheres.  
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Supplementary Table 1. Buffer and vapor diffusion conditions used for ROX crystallization. 
 
Protein complex Sample compositionψ Crystallization conditions Vapor diffusion 
conditions 
SeMet-Mina53•NOG 0.2mM Mina53 + 2mM 
NiCl2 + 5mM NOG  
0.1M Hepes-Na pH 7.5, 12%  
(w/v) PEG 3350, 0.005M CoCl2, 
0.005M MgCl2, 0.005M CdCl2,  
0.005M NiCl2   
Sitting drop (300 nl), 
protein-to-well ratio, 
2:1, 293K 
SeMet-Mina53•2OG 0.25mM Mina53 + 2mM 
NiCl2 + 2mM 2OG  
0.1M Bis-tris propane pH 6.5, 19-
22%  (w/v) PEG 3350, 0.2M 
ammonium sulfate, 0.005M NiCl2   
Sitting drop (300 nl), 
protein-to-well ratio, 
2:1, 293K 
Mina53 Y209C•rpL27a 
G37C 
0.25mM Mina53 + 2mM 
MnCl2 + 2mM 2OG + 
2mM rpL27a (G37C) 
0.1M Bis-tris propane pH 7.5, 
0.2M ammonium sulfate, 21%  
(w/v) PEG 3350, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
NO66 (apo) 0.2mM NO66 0.1M Bis-tris pH 8.5, 10%  (w/v) 
PEG 8000, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
NO66•2,4-pyridine 
dicarboxylate 
0.2mM NO66 + 2mM 
NiCl2 + 1mM 2,4-
pyridin-dicarboxylate  
0.05M Bis-tris pH 6.5, 0.05M 
ammonium sulfate, 30% (v/v) 
pentaerythritol ethoxylate 
Sitting drop (300 nl), 
protein-to-well ratio, 
2:1, 293K 
NO66•NOG 0.2mM NO66 + 2mM 
MnCl2 + 2mM NOG  
0.1M Bis-tris pH 8.5, 10%  (w/v) 
PEG 8000, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
NO66•rpL8G220C 
(complex 1) 
0.2mM NO66 + 2mM 
MnCl2 + 2mM 2mM 
NOG + 2mM rpL8 
(G220C) 
0.1M Hepes-Na pH 7.5, 0.2M 
ammonium acetate, 25% PEG  
(w/v) 4000, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
NO66 299C/C300S 
•rpL8 G220C (complex 
2) 
0.2mM NO66 
L299C/C300S + 2mM 
MnCl2 + 2mM 2mM 
NOG + 2mM rpL8 
(G220C) 
0.1M Hepes-Na pH 7.5, 0.2M 
ammonium acetate, 25% PEG  
(w/v) 4000, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
NO66 S373C 
•rpL8 G214C (complex 
3) 
0.2mM NO66 S373C + 
2mM MnCl2 + 2mM 
2mM NOG + 2mM rpL8 
(G214C) 
0.1M Hepes-Na pH 7.5, 0.2M 
ammonium acetate, 25% PEG  
(w/v) 4000, 0.002M MnCl2 
Sitting drop (300 nl), 
protein-to-well ratio, 
1:1, 293K 
SeMet-ycfD 0.4mM SeMet-ycfD 0.1M Tris.HCl pH 8.5, 0.2M 
lithium sulphate, 1.26 M 
ammonium sulfate, 0.001 M FeCl2 
Sitting drop (200 nl), 
protein-to-well ratio, 
1:1, 293K 
ycfD•2OG 0.25mM ycfD 10mM CoCl2, 50mM 2OG pH 4.2, 
1.5M 1,6 hexanediol, 0.4M 
ammonium dihydrogen phosphate. 
Hanging drop (2 µl), 
protein-to-well ratio, 
1:1, 285K 
ycfD•succinate 0.25mM ycfD 10mM CoCl2; 50mM succinic acid 
pH 4.2, 1.2M 1,6 hexanediol 
Hanging drop (2 µl), 
protein-to-well ratio, 
1:1, 285K 
 
ψ Substrate Peptides used,  rpL27a (G37C): 32RGNAGCLHHHRINFDKYHP50;  
rpL8 (G214C): 205NPVEHPFGGCNHQHIGKPST224;  
rpL8 (G220C): 205NPVEHPFGGGNHQHICKPSTIRRDAPAGRKVGLIA239;  
 
Protein buffers used:  50 mM Hepes-Na pH 7.5, 500 mM NaCl, 5% (v/v) glycerol, 0.5 mM TCEP. 
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Supplementary Table 2. Data collection and refinement statistics of Mina53 complexes 
 
Datasets Mina53 (SeMet) Mina53.NOG Mina53 (SeMet) .2OG Mina53 Y209C. rpL27a 
G37C 
PDB acquisition codes - 2XDV 4BU2 4BXF 
Data collection     
Beamline (Wavelength, Å) SLS X10SA (0.9792) SLS X10SA (0.9528) DLS I04 (0.9699) DLS I02 (0.9795) 
Detector CCD/ Rayonix MX225 CCD/ Rayonix MX225 ADSC Q315r Pilatus 6M 
Data processing MOSFLM19, SCALA20 XDS21, SCALA20 MOSFLM19, SCALA20 MOSFLM19, SCALA20 
Space group P4332 P4332 P4332 P212121 
Cell dimensions     
a, b, c (Å) 183.7, 183.7, 183.7 185.18, 185.18, 185.18 184.63, 184.63, 184.63 70.34, 88.39, 167.18 
α, β, γ (°)  90, 90 ,90 90, 90, 90 90, 90 ,90 90, 90, 90 
No. of molecules/ ASU 1 1 1 2 
No. reflections  34907 (2682)* 27690 (3970)* 64784 (9275)* 
Resolution (Å) 42-3.52 (3.71-3.52)* 29.28-2.57 (2.70-2.57)* 37.69-2.78 (2.93-2.78)* 64.83-2.05 (2.16-2.05)* 
Rsym or Rmerge** 0.345 (0.888)* 0.093 (1.001)* 0.212 (1.470)* 0.110 (0.896)* 
I/σI 16.4 (2.8) 17.0 (2.0)* 20.4 (3.3)* 7.0 (2.0)* 
Completeness (%) 95.8 (71.2) 99.5 (97.0)* 100.0 (100.0)* 98.2 (97.3)* 
Redundancy 38.2 (13.2) 9.4 (7.8)* 40.7 (42.0)* 3.3 (3.4)* 
Wilson B value (Å2)  68.36 55.20 31.34 
 
    
Phasing     
Resolution (Å)  29.28 – 2.57 37.69-2.78 - 
Phasing power  0.44 (anom)/ 0.37 (iso) 0.78 - 
Figure of merit  0.81 0.58 - 
Rcullis (anomalous)  0.95 0.88 - 
 
    
Refinement  BUSTER22 CNS 1.323 CNS 1.323 
Rwork/ Rfree‡  0.197/ 0.229 0.228/ 0.233 0.215/ 0.218 
No. atomsψ     
    -Enzyme (A/B)  3046 3012 3330 (A), 3271 (B) 
    -Ligand  NOG (10) 2OG (10) 2OG (2 × 10) 
    -Substrate  - - 73 (C), 65 (D) 
    -Water  148 122 349 
B-factorsψ     
   -Enzyme (A/B)   65.07 57.26 42.15 (A),  
56.65 (B) 
   -Ligand  41.90 44.32 34.87 (A),  
55.48 (B) 
   -Substrate  - - 41.83 (C),  
65.39 (D) 
   -Water  61.64 53.06 51.27 
R.m.s deviations     
-Bond lengths (Å)   0.0138 0.010 0.008 
-Bond angles (º)  1.83 1.30 1.30 
     
 
*Highest resolution shell shown in parenthesis. 
**Rsym = ∑|I-<I>|/∑I, where I is the intensity of an individual measurement and <I> is the average intensity from multiple observations.  ‡Rfactor = ∑hkl||Fobs(hkl)| − k |Fcalc(hkl)||/ ∑hkl|Fobs(hkl)| for the working set of reflections; Rfree  is the Rfactor for ~5% of the reflections excluded 
from refinement. 
ψPolypeptide chain in parenthesis. 
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Supplementary Table 3. Data collection and refinement statistics of NO66 complexes. 
 
Datasets NO66 Apo NO66.2,4-PDCA NO66.NOG Complex-1 Complex-2 Complex-3 
PDB acquisition 
codes 
XXXX 4DIQ XXXX XXXX XXXX XXXX 
Data collection       
Beamline 
(Wavelength, Å) 
DLS I04-1 
(0.9200) 
SLS X10SA 
(0.9919) 
DLS I04-1 
(0.9200) 
DLS I02 
(0.9795) 
DLS I02 
(0.9795) 
DLS I03 
(1.0719) 
Detector Pilatus 2M CCD/ Rayonix 
MX225 
Pilatus 2M Pilatus 6M-F Pilatus 6M-F Pilatus 6M-F 
Data processing MOSFLM19, 
SCALA20 
HKL200024 MOSFLM19, 
SCALA20 
XDS21, 
SCALA20 
XDS21, 
SCALA20 
XDS21, 
SCALA20 
Space group P21 P21212 P21 C2 C2 C2 
Cell dimensions       
a, b, c (Å) 102.4, 81.56, 
152.0 
78.674, 149.550, 
105.311 
101.4, 80.71, 
151.5 
154.8, 83.5, 
96.87 
155.165, 83.721, 
97.03 
155.39, 84.94, 
97.3 
α, β, γ (°)  90, 94.66, 90 90, 90, 90 90, 94.54, 90 90, 100.2, 90 90, 100.35, 90 90, 100.3, 90 
No. of molecules/ 
ASU 
4 2 4 2 2 2 
No. reflections 128285 (9704)* 47243 (3208)* 131084 (9546)* 217169 (15791)* 190357 (27615)* 181787 (25364)* 
Resolution (Å) 63.72-2.15 
(2.21-2.15)* 
29.46 – 2.40 
(2.49-2.40) * 
81.10-2.15 
(2.21-2.15)* 
44.07-2.51 
(2.58-2.51)* 
44.19-2.23 
(2.35-2.23)* 
47.87-2.30 
(2.42-2.30)* 
Rsym or Rmerge** 0.045 (0.527)* 0.076 (0.637)* 0.079 (0.655)* 0.133 (0.801)* 0.114 (0.763)* 0.089 (0.540)* 
I/σI 13.3 (2.3)* 22.8 (2.1)* 10.2 (2.2)* 7.2 (1.7)* 7.3 (1.8)* 9.9 (2.2)* 
Completeness (%) 95.1 (97.6)* 99.9 (98.6)* 98.9 (97.9)* 99.2 (99.8)* 98.2 (97.8)* 98.1 (93.3)* 
Redundancy 3.3 (3.3)* 5.1 (3.8)* 4.5 (4.4)* 5.5 (5.2)* 3.2 (3.2)* 3.3 (3.4)* 
Wilson B value (Å2) 42.30  37.31 46.10 35.15 35.06 
 
      
Refinement CNS 1.323 REFMAC25 CNS 1.318 CNS 1.323 CNS 1.323 CNS 1.318 
Rwork/ Rfree‡ 0.211/0.218 0.185/0.231 0.196/0.203 0.230/0.234 0.234/0.248 0.211/0.213 
No. atomsψ       
    -Enzyme (A/B) 3660 (A),  
3660 (B),  
3660 (C),  
3660 (D) 
3618 (A),  
3643 (B) 
3660 (A),  
3644 (B),  
3643 (C),  
3654 (D) 
3659 (A),  
3659 (B) 
3644 (A),  
3641 (B) 
3661 (A),  
3657 (B) 
    -Ligand - 2,4-PDCA  
(2 × 14) 
NOG (4 × 10) NOG (2 × 10) NOG (2 × 10) NOG (2 × 10) 
    -Substrate - - - 69 (C),  
69 (D) 
77 (C),  
71 (D) 
84 (C),  
85 (D) 
    -Water 949 120 738 308 355 547 
B-factorsψ       
   -Enzyme (A/B) 39.16 (A),  
41.88 (B), 
51.42 (C),  
54.40 (D) 
58.22 (A),  
33.70 (B) 
36.80 (A),  
46.41 (B),  
38.50 (C),  
48.29 (D) 
56.21 (A),  
53.91 (B) 
37.31 (A),  
36.83 (B) 
37.37 (A),  
35.59 (B) 
   -Ligand - 50.13 (A),  
25.31 (B) 
42.11 (A),  
45.34 (B),  
42.50 (C),  
55.15 (D) 
44.18 (A),  
46.92 (B) 
39.68 (A),  
30.72 (B) 
32.04 (A),  
39.05 (B) 
   -Substrate - - - 91.37 (C),  
90.17 (D) 
59.82 (C),  
46.04 (D) 
64.71 (C),  
61.15 (D) 
   -Water 50.79 41.56 45.89 45.54 37.93 39.64 
R.m.s deviations       
-Bond lengths (Å)  0.008 0.014 0.007 0.008 0.013 0.008 
-Bond angles (º) 1.41 1.68 1.28 1.25 1.35 1.43 
 
*Highest resolution shell shown in parenthesis. 
**Rsym = ∑|I-<I>|/∑I, where I is the intensity y of an individual measurement and <I> is the average intensity from multiple observations.  ‡Rfactor = ∑hkl||Fobs(hkl)| − k |Fcalc(hkl)||/ ∑hkl|Fobs(hkl)| for the working set of reflections; Rfree  is the Rfactor for ~5% of the reflections excluded 
from refinement. 
ψPolypeptide chain in parenthesis. 
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Supplementary Table 4. Data collection and refinement statistics of ycfD complexes. 
 
Datasets ycfD (SeMet/ Oxford) ycfD (SeMet/ Sussex) ycfD.2OG ycfD.Succinate 
PDB acquisition codes XXXX 4LIU 4LIT 
 
4LIV 
Data collection     
Beamline (Wavelength, Å) DLS I03  ESRF BM16 
(0.9798) 
Home Source 
(1.5419) 
Home source 
(1.5419) 
Detector ADSC ADSC Saturn 944+ Saturn 944+ 
Data processing HKL2000 MOSFLM19, SCALA20 MOSFLM19, SCALA20 MOSFLM19, SCALA20 
Space group P43212 P43212 P43212 P43212 
Cell dimensions     
a, b, c (Å) 120.727, 120.727, 
133.593 
75.11, 75.11, 209.95 74.14, 74.14, 208.86 75.01, 75.01, 209.00 
α, β, γ (°)  90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
No. of molecules/ ASU 2 1 1 1 
No. reflections 31129 (3044)* 17365 (2469)* 23737 (3361)* 16951 (2432)* 
Resolution (Å) 44.77-2.60 (2.69-2.60) 47.39-2.70 
(2.85-2.70) 
37.07-2.40 
(2.53-2.40) 
60.94-2.70 
(2.85-2.70) 
Rsym or Rmerge** 0.095 0.142 (0.872) 0.164 (0.730) 0.179 (0.895) 
I/σI 23.8 (1.6) 11.0 (2.0) 11.8 (3.3) 10.7 (2.5) 
Completeness (%) 100 (99.8) 99.9 (100.0) 100.0 (100.0) 99.0 (99.8) 
Redundancy 14.1 (11.2) 6.1 (6.3) 12.9 (12.6) 6.6 (6.6) 
Wilson B value (Å2) 63.9 10.97 22.03 6.34 
 
    
Phasing     
Resolution (Å) 44.77-2.60 47.39-2.70 - - 
Phasing power - 0.766 - - 
Figure of merit 0.58 0.895 - - 
Rcullis (anomalous) - 0.894 - - 
 
    
Refinement PHENIX26 PHENIX26 PHENIX26 PHENIX26 
Rwork/ Rfree‡ 0.195/0.250 0.199/0.236 0.184/0.236 0.195/0.250 
No. atomsψ     
    -Enzyme (A/B) 2907 (A),  
2976 (B) 
2886 2897 2890 
    -Ligand 49 - 10 8 
    -Substrate - - - - 
    -Water 155 113 137 124 
B-factorsψ     
   -Enzyme (A/B) 89.0(A), 73.35(B) 41.20 44.60 43.50 
    -Ligand -  49.91 34.93 
   -Substrate - - - - 
   -Water 66.3 36.80 46.70 40.10 
R.m.s deviations     
-Bond lengths (Å)  0.009 0.003 0.006 0.005 
-Bond angles (º) 1.031 0.792 1.009 0.911 
 
*Highest resolution shell shown in parenthesis. 
**Rsym = ∑|I-<I>|/∑I, where I is the intensity of an individual measurement and <I> is the average intensity from multiple observations.  ‡Rfactor = ∑hkl||Fobs(hkl)| − k |Fcalc(hkl)||/ ∑hkl|Fobs(hkl)| for the working set of reflections; Rfree  is the Rfactor for ~5% of the reflections excluded 
from refinement. 
ψPolypeptide chain in parenthesis. 
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SeMet protein 
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S.S.N., E.S.P. and C.P. (2XDV). 
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Assays R.C. R.C. C.-h.H. and N.J.K. 
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